Q-Line Biotech Q2 Results 2026 (FY27): Revenue ₹152 Cr, PAT ₹20 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Based on Q-Line Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6). H1 FY27 Financials (Page 8 & 6):.
From Q-Line Biotech Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.
How did Q-Line Biotech's revenue grow in the September 2026 quarter?
- H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6).
- Revenue by segment H1 FY27: Instruments 21%, Reagents 72%, Consumables 6%, Services 1% (Page 7).
- Reagent business growth: 19.23% growth during H1 FY27 (Page 5).
- Instrument revenues: Declined 29.71% in H1 FY27, attributed to delayed government orders (Page 5).
- Outlook:
2 more points from Q-Line Biotech Ltd's call on revenue
Create a free account to keep reading this call
What happened to Q-Line Biotech's margins in Q2 FY27?
See what Q-Line Biotech Ltd said on profitability & margins — free account, 30 seconds.
What capex is Q-Line Biotech planning?
- Ramp up Unit 4 manufacturing facility towards full-scale operations in H2 FY27.
- Product licenses for Unit 4 increased from 9 (Sept 30, 2026) to 36 (Nov 5, 2026).
- Unit 4 expected to become fully operational during H2 FY27, supporting scale-up.
- Capitalization of Unit 4 led to higher depreciation in H1 FY27.
- Strategy includes acquisition of 70% stake in Heidelco Medicore for operational consolidation and resource utilization (status: proposed).
2 more points from Q-Line Biotech Ltd's call on capex
Create a free account to keep reading this call
Is Q-Line Biotech raising money or cutting debt?
See what Q-Line Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Q-Line Biotech's order book?
2 more points from Q-Line Biotech Ltd's call on order book
Create a free account to keep reading this call
Continue your research
What Q-Line Biotech's management said in earlier quarters
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Q-Line Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Q-Line Biotech Ltd Q2 FY27 results?
H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6). H1 FY27 Financials (Page 8 & 6):.
What is Q-Line Biotech Ltd share price analysis?
Q-Line Biotech Ltd currently shows a neutral. The stock trades at a P/E of 22.8 with a market cap of ₹1,292 Cr. Investors should review the full earnings analysis for detailed insights.
Is Q-Line Biotech Ltd planning capital expenditure?
Ramp up Unit 4 manufacturing facility towards full-scale operations in H2 FY27.
Keep Q-Line Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
